CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug

CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.